After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback